Overview
- President Luiz Inácio Lula da Silva announced the intention to offer weight‑loss injectable medications free through the SUS to patients with a medical indication during a visit to Minas Gerais on Thursday.
- The Ministry of Health and other officials clarified the announcement is a political commitment that will not become a program until Conitec issues a recommendation, the ministry makes a formal decision and a clinical protocol is defined.
- A government pilot called Real‑Bari at Grupo Hospitalar Conceição is treating about 250 SUS patients with semaglutide and has produced preliminary positive results while it evaluates whether the drug can reduce the need for bariatric surgery.
- Regulatory and market shifts give the plan context: Brazil now lists about 14 registered anti‑obesity products, recent Anvisa approvals expanded competition and Congress is debating measures such as compulsory licensing to address patents and prices.
- The pledge has become an election issue with critics questioning SUS capacity to deliver basic supplies, while officials stress the treatment will be for clinical need only, require specialist follow‑up and be paired with diet and exercise support.